Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roland B Walter

Showing results (1-10 of 281) with videos related to

Pageof 29
Sort By:
Expert Opinion on Biological Therapy|August 29, 2020
Brief overview of antibody-drug conjugate therapy for acute leukemiaRoland B Walter
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 24, 2015
How Do Pretransplantation Peripheral Blood Counts Inform Us about Post-Transplantation Outcomes in Acute Myeloid Leukemia?Roland B Walter
Expert Opinion on Therapeutic Targets|April 23, 2014
The role of CD33 as therapeutic target in acute myeloid leukemiaRoland B Walter
Expert Review of Hematology|March 13, 2014
Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemiaRoland B Walter
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2018
Minimal Residual Disease Testing After Induction Chemotherapy for Acute Myeloid Leukemia: Moving Beyond Prognostication?Roland B Walter
Expert Opinion on Investigational Drugs|March 15, 2018
Investigational CD33-targeted therapeutics for acute myeloid leukemiaRoland B Walter
Immunotherapy|September 9, 2016
Antigen-directed therapies: an effective tool in acute myeloid leukemia?Roland B Walter
Leukemia|November 17, 2023
Perspective on measurable residual disease testing in acute myeloid leukemiaRoland B Walter
Current Opinion in Hematology|January 15, 2016
Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy?Roland B Walter
Clinical Advances in Hematology & Oncology : H&O|March 19, 2021
The evolving use of gemtuzumab ozogamicin in acute myeloid leukemiaRoland B Walter
Pageof 29

Showing results (1-10 of 281) with videos related to

Sort By:
Pageof 29
Expert Opinion on Biological Therapy|August 29, 2020
Brief overview of antibody-drug conjugate therapy for acute leukemiaRoland B Walter
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 24, 2015
How Do Pretransplantation Peripheral Blood Counts Inform Us about Post-Transplantation Outcomes in Acute Myeloid Leukemia?Roland B Walter
Expert Opinion on Therapeutic Targets|April 23, 2014
The role of CD33 as therapeutic target in acute myeloid leukemiaRoland B Walter
Expert Review of Hematology|March 13, 2014
Biting back: BiTE antibodies as a promising therapy for acute myeloid leukemiaRoland B Walter
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2018
Minimal Residual Disease Testing After Induction Chemotherapy for Acute Myeloid Leukemia: Moving Beyond Prognostication?Roland B Walter
Expert Opinion on Investigational Drugs|March 15, 2018
Investigational CD33-targeted therapeutics for acute myeloid leukemiaRoland B Walter
Immunotherapy|September 9, 2016
Antigen-directed therapies: an effective tool in acute myeloid leukemia?Roland B Walter
Leukemia|November 17, 2023
Perspective on measurable residual disease testing in acute myeloid leukemiaRoland B Walter
Current Opinion in Hematology|January 15, 2016
Should acute myeloid leukemia patients with actionable targets be offered investigational treatment after failing one cycle of standard induction therapy?Roland B Walter
Clinical Advances in Hematology & Oncology : H&O|March 19, 2021
The evolving use of gemtuzumab ozogamicin in acute myeloid leukemiaRoland B Walter
Pageof 29